Month: June 2026
-
Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs
Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth BOSTON, MA, June 30, 2026 – Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply…